| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/17/2005 | WO2005014647A1 Product and composition containing a concholepas concholepas hemocyanin (cch) subunit a, and a method of use thereof |
| 02/17/2005 | WO2005014645A2 Pedf-r receptor and uses |
| 02/17/2005 | WO2005014644A1 Gene expressed in breast cancer and methods of use |
| 02/17/2005 | WO2005014629A2 Protein from photobacterium damselae and use thereof |
| 02/17/2005 | WO2005014618A2 Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
| 02/17/2005 | WO2005014612A1 Novel splice variant of ctla-4 |
| 02/17/2005 | WO2005014110A1 Cpg-packaged liposomes |
| 02/17/2005 | WO2005014041A2 Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases |
| 02/17/2005 | WO2005014040A2 Antigen delivery system |
| 02/17/2005 | WO2005014039A2 Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative diseases |
| 02/17/2005 | WO2005014038A1 Novel vaccine containing adjuvant capable of inducing mucosal immunity |
| 02/17/2005 | WO2005014037A2 Polysaccharide-protein conjugate vaccines |
| 02/17/2005 | WO2005014036A1 Targeted therapeutic vaccine against p-glycoprotein 170 for inhibiting multi-drug resistance in the treatment of cancers |
| 02/17/2005 | WO2005013920A2 Newcastle disease virus administration |
| 02/17/2005 | WO2005013918A2 Compositions, methods and kits relating to poxvirus subunit vaccines |
| 02/17/2005 | WO2005013912A2 Anti-fcrn antibodies for treatment of auto/allo immune conditions |
| 02/17/2005 | WO2005013904A2 Sars nucleic acids, proteins, vaccines, and uses thereof |
| 02/17/2005 | WO2005013899A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 02/17/2005 | WO2005013898A2 Novel targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax |
| 02/17/2005 | WO2005013896A2 Programmed immune responses using a vaccination node |
| 02/17/2005 | WO2005013891A2 Vaccines using pattern recognition receptor-ligand:lipid complexes |
| 02/17/2005 | WO2005013889A2 Truncated fragments of alpha-synuclein in lewy body disease |
| 02/17/2005 | WO2005013802A2 Trefoil factor 3 (tff3) as a target for anti-cancer therapy |
| 02/17/2005 | WO2005004911A3 Adjuvant combinations of liposomes and mycobacterial lipids for immunization compositions and vaccines |
| 02/17/2005 | WO2004113547A3 Potent combinations of mrna transport elements |
| 02/17/2005 | WO2004108157A3 Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
| 02/17/2005 | WO2004091551A3 Anti-tumor vasculature effects of human serum albumin derivatives |
| 02/17/2005 | WO2004083397A3 Process for increasing rsv surface glycoprotein yields using a mutant strain of rsv |
| 02/17/2005 | WO2004081028A3 Allergen peptide fragments and use thereof |
| 02/17/2005 | WO2004074432A3 Antibody vaccine conjugates and uses therefor |
| 02/17/2005 | WO2004067564A3 Compositions against cancer antigen liv-1 and uses thereof |
| 02/17/2005 | WO2004047740A3 Composition and method for treating lupus nephritis |
| 02/17/2005 | WO2004046310A3 Novel mouse polypeptides encoded by polynucleotides and methods of their use |
| 02/17/2005 | WO2004005457A3 Tfc/ beta-catenin regulated genes for treating cancer |
| 02/17/2005 | WO2004000872A3 Improved alphavirus vectors having attenuated virion structural proteins |
| 02/17/2005 | WO2003101396A3 Helper virus-free herpesvirus amplicon particles and uses thereof |
| 02/17/2005 | WO2003070187A3 Fusion proteins of mycobacterium tuberculosis |
| 02/17/2005 | WO2003050258A3 Endogenous retrovirus polypeptides linked to oncogenic transformation |
| 02/17/2005 | WO2003025131A3 Protein modification and maintenance molecules |
| 02/17/2005 | WO2003004051A3 Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle |
| 02/17/2005 | WO2002088304A3 Compositions and methods for suppressing immune responses |
| 02/17/2005 | WO2002083714A3 Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby |
| 02/17/2005 | WO2002074913A3 Nucleic acid-associated proteins |
| 02/17/2005 | US20050038113 Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease |
| 02/17/2005 | US20050037985 Administering CpG oligonucleotide to patient infected with human immunodeficiency virus |
| 02/17/2005 | US20050037972 Bactericides; using polypeptides |
| 02/17/2005 | US20050037970 Protein devived from Schistosome parasites |
| 02/17/2005 | US20050037969 Molecular interactions in hematopoietic cells |
| 02/17/2005 | US20050037956 Screening method for agents useful in treating diabetes |
| 02/17/2005 | US20050037955 Bactericides; fungicides; isolated polypeptides; inflammatory bowel disorders; infections |
| 02/17/2005 | US20050037464 Prokineticin polypeptides, related compositions and methods |
| 02/17/2005 | US20050037462 Expression vector comprising nucleotide sequences coding g protein for use in generating immunoglobulins for use in prevention, treatment and diagnosis of cell proliferative disorders |
| 02/17/2005 | US20050037449 Agent for controlling circadian rhythm disorder |
| 02/17/2005 | US20050037445 analyzing molecules expressed on the cell surface of cancer cells and comparing to nonmalignant cells; screening for cancer specific promoters to be used singly or in combination for delivery and expression of therapeutic genes for treatment of cancer |
| 02/17/2005 | US20050037444 Method for identification isolation and production of antigens to a specific pathogen |
| 02/17/2005 | US20050037443 Detection of sarcocystis neurona |
| 02/17/2005 | US20050037439 Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same |
| 02/17/2005 | US20050037419 Compositions and methods relating to lung specific genes and proteins |
| 02/17/2005 | US20050037417 Screening peptide library for amino acid sequences which specifically target/hybridize to brain and kidney tissue; immunodiagnostics; tissue targeted therapy |
| 02/17/2005 | US20050037403 Immunomodulatory oligonucleotides |
| 02/17/2005 | US20050037345 Gene with polynucleopotide codes with polypeptide with amino acid sequences for domains and molecular hybridization for gene expression and cancer |
| 02/17/2005 | US20050037340 Immunoglobulin for use in detection of simian and lymphadenopathy associated viral infection in mammals; immunodiagnostics |
| 02/17/2005 | US20050037339 Methods of selecting internalizing antibodies |
| 02/17/2005 | US20050037337 Papilloma virus sequences |
| 02/17/2005 | US20050037336 Hepatitis X virus for use in generation of antibody and vaccine compositions for use in diagnosis, prevention and treatment viral infection; immunotherapeutic and diagnostics |
| 02/17/2005 | US20050037085 Microencapsulated DNA for vaccination and gene therapy |
| 02/17/2005 | US20050037026 such as Alzheimer's disease; amyloid precursor proteins; comprises diphtheria toxoid as carrier |
| 02/17/2005 | US20050037021 For primates; p42 nucleic acid encoding a p42 polypeptide from the C-terminal processing fragment of Plasmodium falciparum major merozoite surface protein gp195 which hybridizes under high stringency conditions |
| 02/17/2005 | US20050037020 Hydrophilic eimeria polypeptide; genetic engineering |
| 02/17/2005 | US20050037019 Vaccines for Chlamydia psittaci infections |
| 02/17/2005 | US20050037017 Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins |
| 02/17/2005 | US20050037016 determining whether a mouse is infected with murine norovirus-1 by determining presence, absence or quantity of antibody against MNV-1 a sample of a mouse; the antibody binds to MNV-1 deposited as American Type Culture Collection (ATCC) Deposit No. PTA-5935 or to a polypeptide encoded by it |
| 02/17/2005 | US20050037015 Immunogenic compositions comprising an antigen and a purified m protein from respiratory syncytial virus |
| 02/17/2005 | US20050037014 T helper cell epitopes |
| 02/17/2005 | US20050037013 Prevention and treatment of synucleinopathic and amyloidogenic disease |
| 02/17/2005 | US20050037012 A polypeptide covalently attached with a polyethylene glycol propionaldehyde group having anti-hepatitis C activity |
| 02/17/2005 | US20050037011 Associated with a reduction in wingless-related MMTV integration site 5a (Wnt5a) gene expression or activity or protein activity; assessing the level of expression of cyclin D1 or phosphorylation of protein kinase C, calmodulin kinase II, dishevelled, or LEF-1; leukemias, lymphomas, and myelomas |
| 02/17/2005 | US20050037010 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| 02/17/2005 | US20050037006 Antithrombotic agents |
| 02/17/2005 | US20050037005 5c8 Antigen |
| 02/17/2005 | US20050037004 An aglycosylated antibody having a binding affinity for the CD3 antigen complex; antiinflammatory, antiarthritic agents |
| 02/17/2005 | US20050037003 Administering a soluble lymphotoxin- beta receptor, an antibody directed against LT- beta receptor, or an antibody directed against surface LT ligand with a carrier; multiple sclerosis, vision defects, psoriasis, inflammatory bowel disease; antidiabetic agents |
| 02/17/2005 | US20050037001 APC targeting conjugate, an antigen-presenting cell contacted with such conjugate, their medical use, and methods of production |
| 02/17/2005 | US20050036995 Immunogens; tumor antigens; kits |
| 02/17/2005 | US20050036991 For preventing and/or treating transplant/xenotransplant rejection; interleukin-1B converting enzyme inhibitors |
| 02/17/2005 | US20050036987 Suicide gene-containing strains of bacteria, fungi, and protists; tumor specific shigella species |
| 02/17/2005 | US20050036985 Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 02/17/2005 | US20050036984 Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof |
| 02/17/2005 | US20050036951 Methods of treating lung diseases |
| 02/17/2005 | DE10332854A1 Verwendung des neu-identifizierten humanen Gens 7a5/Prognostin für Tumordiagnostik und Tumortherapie Using the newly-identified human gene 7a5 / Prognostin for tumor diagnosis and tumor therapy |
| 02/17/2005 | CA2844154A1 Polysaccharide-protein conjugate vaccines |
| 02/17/2005 | CA2807534A1 Methods of producing influenza vaccine compositions |
| 02/17/2005 | CA2544240A1 Cpg-packaged liposomes |
| 02/17/2005 | CA2537555A1 Compositions and methods for the therapy and diagnosis of lung cancer |
| 02/17/2005 | CA2535517A1 Product comprising a c4bp core protein and a monomeric antigen, and its use |
| 02/17/2005 | CA2534973A1 Anti-fcrn antibodies for treatment of auto/allo immune conditions |
| 02/17/2005 | CA2534909A1 P16 mediated regulation of nmda receptors |
| 02/17/2005 | CA2534898A1 Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
| 02/17/2005 | CA2534870A1 Polysaccharide-protein conjugate vaccines |
| 02/17/2005 | CA2534812A1 Mutations in ion channels |